Ozempic Personality With Dr Spencer Nadolsky

Ozempic Personality With Dr Spencer Nadolsky

This conversation dives headfirst into one of the most controversial and least understood side effects of GLP-1 medications, what many are now calling the “Ozempic personality.” In this candid interview, Dr. Spencer Nadolsky joins On The Pen to unpack the growing reports of anhedonia, a flattening of motivation, desire, and emotional highs that some patients experience, especially at higher doses of tirzepatide and similar therapies.


What starts as a discussion about how these medications work in the brain quickly turns into something much deeper. We explore how GLP-1 and GIP receptor agonists don’t just reduce hunger, they fundamentally alter the brain’s reward system, dampening cravings, food noise, and in some cases, the very drive to seek pleasure at all. That is where the idea of the “Ozempic personality” begins to take shape, not as a diagnosis, but as a shared patient experience that is only now being taken seriously.


Dave opens up about his own journey, spending years at the highest dose and slowly realizing that while the medication gave him control over food and blood sugar, it also quietly muted parts of his identity. Hobbies faded. Motivation shifted. The highs and lows of life became more… flat. And it wasn’t until stepping away that he could see the contrast clearly.


Dr. Nadolsky brings clinical perspective to match the lived experience, explaining how this isn’t classic depression, but something more nuanced. Patients aren’t necessarily sad, they just stop wanting things. He shares how often this shows up in his practice, how he identifies it, and most importantly, how adjusting dose rather than stopping treatment altogether can restore balance.


The conversation also raises bigger questions about transparency in clinical trials, what drug companies knew about these “anti-hedonic” effects, and why something so impactful may not have been formally tracked. At the same time, both Dave and Dr. Nadolsky emphasize what matters most, these medications are still life changing, even life saving, but they are not one size fits all.


If you’ve ever felt like something changed beyond just your appetite while on a GLP-1, this is the conversation you’ve been waiting for. It puts language to an experience thousands are having but struggling to explain, and it gives you something even more important, a path forward.


Watch the full interview to understand the reality behind the “Ozempic personality,” how to recognize it, and how to work with your doctor to find your own sweet spot.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(207)

  We’re Solving Obesity. Now Who Pays for It?

We’re Solving Obesity. Now Who Pays for It?

This week on On The Pen, the GLP-1 story is moving in two very different directions.The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its con...

2 Sep 24min

GLP-1 Coverage Is COLLAPSING in 2027

GLP-1 Coverage Is COLLAPSING in 2027

GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health.In this episode of the On The Pen Podcast, Dave Knapp breaks ...

26 Aug 34min

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity treatment in America.But gett...

18 Aug 45min

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

Https://www.otplinks.comBased on the transcript flow, here’s a clean YouTube description with chapter timestamps. The transcript itself doesn’t include timecodes, so these are estimated from speaking ...

12 Aug 31min

Eli Lilly Earnings Call Recap: Retatrutide News

Eli Lilly Earnings Call Recap: Retatrutide News

https://www.otplinks.com

7 Aug 59min

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes i...

4 Aug 18min

Retatrutide Biologic Battle: The Story Gets Bigger

Retatrutide Biologic Battle: The Story Gets Bigger

https://www.otplinks.comhttps://www.voafit.com/otpEpisode Referenced: https://www.youtube.com/watch?v=K8kaSoFCZ0c&t=41sThe retatrutide biologic fight is bigger than folks understand.This breakdown cov...

28 Juli 20min

GLP-1 Showdown: Inside The High Stakes War over Patients

GLP-1 Showdown: Inside The High Stakes War over Patients

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.In this episode...

22 Juli 27min

Populärt inom Hälsa

somna-med-henrik
rss-jossan-nina
bullfika
inga-beiga-morsor
rss-bara-en-till-om-beroende-medberoende
rss-vuxna-pa-latsas
not-fanny-anymore
rss-viktmedicinpodden
sexnoveller-deluxe
angestpodden
johannes-hansen-podcast
sa-in-i-sjalen
rss-hos-psykologen
rss-basta-livet
tyngre-traningssnack
sova-med-dan-horning
rss-traningsklubben
medicinvetarna
halsorevolutionen
rss-angra-inget-3